Skip to main content
Erschienen in: Abdominal Radiology 1/2016

01.01.2016 | Review Paper

Prognostic significance of parameters from pretreatment 18F-FDG PET in hepatocellular carcinoma: a meta-analysis

verfasst von: Da-Wei Sun, Lin An, Feng Wei, Lin Mu, Xiao-Ju Shi, Chuan-Lei Wang, Zheng-Wei Zhao, Teng-Fei Li, Guo-Yue Lv

Erschienen in: Abdominal Radiology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The prognostic value of 18F-deoxyglucose positron emission tomography (18F-FDG PET) on hepatocellular carcinoma (HCC) remains inconclusive. This study aims to investigate the prognostic role of pretreatment 18F-FDG PET on HCC patients by meta-analysis.

Methods

PubMed, Embase, Cochrane library, and Wanfang databases were searched until June 2015. Hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were synthesized by Stata 10.0, and the combined results were used as effective values.

Results

Twenty-two studies containing a total of 1721 patients were identified. According to random-effect model, meta-analysis results showed that high Tumor SUV/Liver SUV (Tsuv/Lsuv) ratio was significantly associated with poorer overall survival (OS) (HR = 2.04; 95% CI 1.50–2.79; P = 0.000) and poorer disease-free survival (HR = 7.17; 95% CI 3.58–14.36; P = 0.000); and high Tumor SUV (Tsuv) value was also correlated with poor OS (HR = 1.53; 95% CI 1.26–1.87; P = 0.000). Meanwhile, subgroup analysis results showed that the significant association above was not altered by study sample size, parameter cutoff value, analytic method, and follow-up period, but there was no significant association between Tsuv/Lsuv ratio and OS in patients who underwent resection (HR = 1.71; 95% CI 1.00–2.92; P = 0.052).

Conclusions

Both high Tsuv/Lsuv ratio and high Tsuv value are associated with poor prognosis in HCC patients. Therefore, pretreatment 18F-FDG PET is a useful tool in predicting the prognosis of HCC patients. More studies with explicit treatment modalities are required to investigate the prognostic value of pretreatment 18F-FDG PET on HCC patients.
Literatur
1.
Zurück zum Zitat Torre LA, Bray F, Siegel RL, et al. (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108CrossRefPubMed Torre LA, Bray F, Siegel RL, et al. (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108CrossRefPubMed
2.
Zurück zum Zitat Altekruse SF, McGlynn KA, Dickie LA, et al. (2012) Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992–2008. Hepatology 55(2):476–482CrossRefPubMed Altekruse SF, McGlynn KA, Dickie LA, et al. (2012) Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992–2008. Hepatology 55(2):476–482CrossRefPubMed
3.
Zurück zum Zitat Maluccio M, Covey A (2012) Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 62(6):394–399CrossRefPubMed Maluccio M, Covey A (2012) Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 62(6):394–399CrossRefPubMed
4.
Zurück zum Zitat Donswijk ML, Hess S, Mulders T, et al. (2014) [18F]Fluorodeoxyglucose PET/computed tomography in gastrointestinal malignancies. PET Clin 9(4):421–441CrossRefPubMed Donswijk ML, Hess S, Mulders T, et al. (2014) [18F]Fluorodeoxyglucose PET/computed tomography in gastrointestinal malignancies. PET Clin 9(4):421–441CrossRefPubMed
5.
Zurück zum Zitat Gauthé M, Richard-Molard M, Cacheux W, et al. (2015) Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers. Dig Liver Dis 47(6):443–454CrossRefPubMed Gauthé M, Richard-Molard M, Cacheux W, et al. (2015) Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers. Dig Liver Dis 47(6):443–454CrossRefPubMed
6.
Zurück zum Zitat Wang Z, Chen JQ, Liu JL, et al. (2013) FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis. World J Gastroenterol 19(29):4808–4817PubMedCentralCrossRefPubMed Wang Z, Chen JQ, Liu JL, et al. (2013) FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis. World J Gastroenterol 19(29):4808–4817PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Maffione AM, Marzola MC, Capirci C, et al. (2015) Value of (18)F-FDG PET for predicting response to neoadjuvant therapy in rectal cancer: systematic review and meta-analysis. AJR Am J Roentgenol 204(6):1261–1268CrossRefPubMed Maffione AM, Marzola MC, Capirci C, et al. (2015) Value of (18)F-FDG PET for predicting response to neoadjuvant therapy in rectal cancer: systematic review and meta-analysis. AJR Am J Roentgenol 204(6):1261–1268CrossRefPubMed
8.
Zurück zum Zitat Li C, Lan X, Yuan H, et al. (2014) 18F-FDG PET predicts pathological response to preoperative chemoradiotherapy in patients with primary rectal cancer: a meta-analysis. Ann Nucl Med 28(5):436–446CrossRefPubMed Li C, Lan X, Yuan H, et al. (2014) 18F-FDG PET predicts pathological response to preoperative chemoradiotherapy in patients with primary rectal cancer: a meta-analysis. Ann Nucl Med 28(5):436–446CrossRefPubMed
9.
Zurück zum Zitat Jones M, Hruby G, Solomon M, et al. (2015) Diagnostic Value of <sup> 18 </sup> F-FDG PET/CT in detecting local recurrent colorectal cancer: a pooled analysis of 26 individual studies. Cell Biochem Biophys. [Epub ahead of print] Jones M, Hruby G, Solomon M, et al. (2015) Diagnostic Value of <sup> 18 </sup> F-FDG PET/CT in detecting local recurrent colorectal cancer: a pooled analysis of 26 individual studies. Cell Biochem Biophys. [Epub ahead of print]
10.
Zurück zum Zitat Lin CY, Chen JH, Liang JA, et al. (2011) 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Eur J Radiol 81(9):2417–2422CrossRefPubMed Lin CY, Chen JH, Liang JA, et al. (2011) 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Eur J Radiol 81(9):2417–2422CrossRefPubMed
11.
Zurück zum Zitat Parmar MK, Torri V, Stewart L (1988) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17(24):2815–2834CrossRef Parmar MK, Torri V, Stewart L (1988) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17(24):2815–2834CrossRef
12.
Zurück zum Zitat Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558CrossRefPubMed Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558CrossRefPubMed
13.
Zurück zum Zitat Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101CrossRefPubMed Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101CrossRefPubMed
14.
Zurück zum Zitat Egger M, Davey Smith G, Schneider M, et al. (1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315(7109):629–634CrossRef Egger M, Davey Smith G, Schneider M, et al. (1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315(7109):629–634CrossRef
16.
Zurück zum Zitat Song HJ, Cheng JY, Hu SL, et al. (2015) Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE. Clin Radiol 70(2):128–137CrossRefPubMed Song HJ, Cheng JY, Hu SL, et al. (2015) Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE. Clin Radiol 70(2):128–137CrossRefPubMed
17.
Zurück zum Zitat Kim YK, Kim SH, Lee SD, et al. (2015) Pretransplant serum levels of C-reactive protein predict prognoses in patients undergoing liver transplantation for hepatocellular carcinoma. Transplant Proc 47(3):686–693CrossRefPubMed Kim YK, Kim SH, Lee SD, et al. (2015) Pretransplant serum levels of C-reactive protein predict prognoses in patients undergoing liver transplantation for hepatocellular carcinoma. Transplant Proc 47(3):686–693CrossRefPubMed
18.
Zurück zum Zitat Kim MJ, Kim YS, Cho YH, et al. (2015) Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization. Korean J Intern Med 30(3):308–315PubMedCentralCrossRefPubMed Kim MJ, Kim YS, Cho YH, et al. (2015) Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization. Korean J Intern Med 30(3):308–315PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Chang ZF, Song P, Wang MQ, et al. (2014) Value of 18F-FDG PET in preoperative TACE of hepatocellular carcinoma. Chin J Oncol 36(5):377–380 Chang ZF, Song P, Wang MQ, et al. (2014) Value of 18F-FDG PET in preoperative TACE of hepatocellular carcinoma. Chin J Oncol 36(5):377–380
20.
Zurück zum Zitat Xu ZQ, Zhang XS, Zhang LQ, et al. (2014) 18F-FDG PET/CT in predicting tumor recurrence for hepatocellular carcinoma after liver transplantation. Chin J Organ Transplant 35(6):341–344 Xu ZQ, Zhang XS, Zhang LQ, et al. (2014) 18F-FDG PET/CT in predicting tumor recurrence for hepatocellular carcinoma after liver transplantation. Chin J Organ Transplant 35(6):341–344
21.
Zurück zum Zitat Han JH, Kim DG, Na GH, et al. (2014) Evaluation of prognostic factors on recurrence after curative resections for hepatocellular carcinoma. World J Gastroenterol 20(45):17132–17140PubMedCentralCrossRefPubMed Han JH, Kim DG, Na GH, et al. (2014) Evaluation of prognostic factors on recurrence after curative resections for hepatocellular carcinoma. World J Gastroenterol 20(45):17132–17140PubMedCentralCrossRefPubMed
22.
Zurück zum Zitat Simoneau E, Hassanain M, Madkhali A, et al. (2014) (18)F-Fluorodeoxyglucose positron-emission tomography could have a prognostic role in patients with advanced hepatocellular carcinoma. Curr Oncol 21(4):e551–e556PubMedCentralCrossRefPubMed Simoneau E, Hassanain M, Madkhali A, et al. (2014) (18)F-Fluorodeoxyglucose positron-emission tomography could have a prognostic role in patients with advanced hepatocellular carcinoma. Curr Oncol 21(4):e551–e556PubMedCentralCrossRefPubMed
23.
Zurück zum Zitat Kawamura E, Shiomi S, Kotani K, et al. (2014) Positioning of 18F-fluorodeoxyglucose-positron emission tomography imaging in the management algorithm of hepatocellular carcinoma. J Gastroenterol Hepatol 29(9):1722–1727CrossRefPubMed Kawamura E, Shiomi S, Kotani K, et al. (2014) Positioning of 18F-fluorodeoxyglucose-positron emission tomography imaging in the management algorithm of hepatocellular carcinoma. J Gastroenterol Hepatol 29(9):1722–1727CrossRefPubMed
24.
Zurück zum Zitat Ahn SG, Jeon TJ, Lee SD, et al. (2013) A survival benefit of major hepatectomy for hepatocellular carcinoma identified by preoperative [18F] fluorodeoxyglucose positron emission tomography in patients with well-preserved hepatic function. Eur J Surg Oncol 39(9):964–973CrossRefPubMed Ahn SG, Jeon TJ, Lee SD, et al. (2013) A survival benefit of major hepatectomy for hepatocellular carcinoma identified by preoperative [18F] fluorodeoxyglucose positron emission tomography in patients with well-preserved hepatic function. Eur J Surg Oncol 39(9):964–973CrossRefPubMed
25.
Zurück zum Zitat Detry O, Govaerts L, Deroover A, et al. (2015) Prognostic value of (18)F-FDG PET/CT in liver transplantation for hepatocarcinoma. World J Gastroenterol 21(10):3049–3054PubMedCentralCrossRefPubMed Detry O, Govaerts L, Deroover A, et al. (2015) Prognostic value of (18)F-FDG PET/CT in liver transplantation for hepatocarcinoma. World J Gastroenterol 21(10):3049–3054PubMedCentralCrossRefPubMed
26.
Zurück zum Zitat Kim JW, Seong J, Yun M, et al. (2012) Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 82(3):1172–1178CrossRefPubMed Kim JW, Seong J, Yun M, et al. (2012) Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 82(3):1172–1178CrossRefPubMed
27.
Zurück zum Zitat Song MJ, Bae SH, IeR Yoo, et al. (2012) Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol 18(25):3215–3222PubMedCentralPubMed Song MJ, Bae SH, IeR Yoo, et al. (2012) Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol 18(25):3215–3222PubMedCentralPubMed
28.
Zurück zum Zitat Kitamura K, Hatano E, Higashi T, et al. (2012) Preoperative FDG-PET predicts recurrence patterns in hepatocellular carcinoma. Ann Surg Oncol 19(1):156–162CrossRefPubMed Kitamura K, Hatano E, Higashi T, et al. (2012) Preoperative FDG-PET predicts recurrence patterns in hepatocellular carcinoma. Ann Surg Oncol 19(1):156–162CrossRefPubMed
29.
Zurück zum Zitat Kornberg A, Küpper B, Tannapfel A, et al. (2012) Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. Liver Transpl 18(1):53–61CrossRefPubMed Kornberg A, Küpper B, Tannapfel A, et al. (2012) Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. Liver Transpl 18(1):53–61CrossRefPubMed
30.
Zurück zum Zitat Shin DY, Han SW, Oh DY, et al. (2011) Prognostic implication of (18)F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study. Cancer Chemother Pharmacol 68(1):165–175CrossRefPubMed Shin DY, Han SW, Oh DY, et al. (2011) Prognostic implication of (18)F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study. Cancer Chemother Pharmacol 68(1):165–175CrossRefPubMed
31.
Zurück zum Zitat Kim BK, Kang WJ, Kim JK, et al. (2011) 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer 117(20):4779–4787CrossRefPubMed Kim BK, Kang WJ, Kim JK, et al. (2011) 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer 117(20):4779–4787CrossRefPubMed
32.
Zurück zum Zitat Lee JW, Paeng JC, Kang KW, et al. (2009) Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 50(5):682–687CrossRefPubMed Lee JW, Paeng JC, Kang KW, et al. (2009) Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 50(5):682–687CrossRefPubMed
33.
Zurück zum Zitat Paudyal B, Paudyal P, Oriuchi N, et al. (2008) Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma. Int J Oncol 33(5):1047–1054PubMed Paudyal B, Paudyal P, Oriuchi N, et al. (2008) Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma. Int J Oncol 33(5):1047–1054PubMed
34.
Zurück zum Zitat Yang SH, Suh KS, Lee HW, et al. (2006) The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 12(11):1655–1660CrossRefPubMed Yang SH, Suh KS, Lee HW, et al. (2006) The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 12(11):1655–1660CrossRefPubMed
35.
Zurück zum Zitat Hatano E, Ikai I, Higashi T, et al. (2006) Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg 30(9):1736–1741CrossRefPubMed Hatano E, Ikai I, Higashi T, et al. (2006) Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg 30(9):1736–1741CrossRefPubMed
36.
Zurück zum Zitat Kong YH, Han CJ, Lee SD, et al. (2004) Positron emission tomography with fluorine-18-fluorodeoxyglucose is useful for predicting the prognosis of patients with hepatocellular carcinoma. Korean J Hepatol 10(4):279–287PubMed Kong YH, Han CJ, Lee SD, et al. (2004) Positron emission tomography with fluorine-18-fluorodeoxyglucose is useful for predicting the prognosis of patients with hepatocellular carcinoma. Korean J Hepatol 10(4):279–287PubMed
37.
Zurück zum Zitat Shiomi S, Nishiguchi S, Ishizu H, et al. (2001) Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 96(6):1877–1880CrossRefPubMed Shiomi S, Nishiguchi S, Ishizu H, et al. (2001) Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 96(6):1877–1880CrossRefPubMed
38.
40.
Zurück zum Zitat Niu ZS, Niu XJ, Wang M (2015) Management of hepatocellular carcinoma: predictive value of immunohistochemical markers for postoperative survival. World J Hepatol 7(1):7–27PubMedCentralCrossRefPubMed Niu ZS, Niu XJ, Wang M (2015) Management of hepatocellular carcinoma: predictive value of immunohistochemical markers for postoperative survival. World J Hepatol 7(1):7–27PubMedCentralCrossRefPubMed
41.
Zurück zum Zitat Zhou L, Rui JA, Wang SB, et al. (2014) Early recurrence in large hepatocellular carcinoma after curative hepatic resection: prognostic significance and risk factors. Hepatogastroenterology 61(135):2035–2041PubMed Zhou L, Rui JA, Wang SB, et al. (2014) Early recurrence in large hepatocellular carcinoma after curative hepatic resection: prognostic significance and risk factors. Hepatogastroenterology 61(135):2035–2041PubMed
Metadaten
Titel
Prognostic significance of parameters from pretreatment 18F-FDG PET in hepatocellular carcinoma: a meta-analysis
verfasst von
Da-Wei Sun
Lin An
Feng Wei
Lin Mu
Xiao-Ju Shi
Chuan-Lei Wang
Zheng-Wei Zhao
Teng-Fei Li
Guo-Yue Lv
Publikationsdatum
01.01.2016
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 1/2016
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-015-0603-9

Weitere Artikel der Ausgabe 1/2016

Abdominal Radiology 1/2016 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

13.04.2024 Klinik aktuell Kongressbericht

Die Teilnehmer eines Forums beim DGIM-Kongress waren sich einig: Fehler in der Medizin sind häufig in ungeeigneten Prozessen und mangelnder Kommunikation begründet. Gespräche mit Patienten und im Team können helfen.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.